abediterol

Uses your system voice; voice and rate in settings.

Q4666480Snapshot

≈ 1 min read

Names in other languages

  • Englishabediterol
  • shAbediterol
  • СрпскиAbediterol
  • Tiếng ViệtAbediterol
  • فارسیآبدیترول

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

Abediterol (INN; development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it has never been marketed.

History

Abediterol was under development by the Spanish pharmaceutical company Almirall and reached Phase II clinical trials, but was discontinued in 2021. Its coformulation with mometasone furoate also progressed to Phase II clinical trials, but was discontinued in 2019.

Mechanism of action

Abediterol is an ultra-long-acting β 2 agonist (ultra-LABA).

Text derived from https://en.wikipedia.org/w/index.php?oldid=1329472548 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

No external citation was extracted for this revision. That is a statement about the source, not a claim that none exists.